Schroder Investment Management Group’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-137,341
| Closed | -$1.39M | – | 1275 |
|
|
2022
Q4 | $1.39M | Buy |
137,341
+4,789
| +4% | +$48.3K | ﹤0.01% | 1007 |
|
|
2022
Q3 | $2.97M | Buy |
132,552
+68,673
| +108% | +$1.54M | ﹤0.01% | 868 |
|
|
2022
Q2 | $1.58M | Buy |
63,879
+998
| +2% | +$24.7K | ﹤0.01% | 1007 |
|
|
2022
Q1 | $2.51M | Buy |
62,881
+15,493
| +33% | +$617K | ﹤0.01% | 970 |
|
|
2021
Q4 | $2.77M | Buy |
47,388
+14,948
| +46% | +$875K | ﹤0.01% | 868 |
|
|
2021
Q3 | $1.92M | Sell |
32,440
-26,794
| -45% | -$1.59M | ﹤0.01% | 991 |
|
|
2021
Q2 | $5.14M | Buy |
59,234
+14,226
| +32% | +$1.23M | 0.01% | 823 |
|
|
2021
Q1 | $3.71M | Sell |
45,008
-32,943
| -42% | -$2.72M | ﹤0.01% | 885 |
|
|
2020
Q4 | $7.09M | Sell |
77,951
-9,957
| -11% | -$905K | 0.01% | 723 |
|
|
2020
Q3 | $3.35M | Buy |
87,908
+7,519
| +9% | +$286K | 0.01% | 801 |
|
|
2020
Q2 | $2.76M | Sell |
80,389
-12,614
| -14% | -$433K | 0.01% | 769 |
|
|
2020
Q1 | $2.31M | Buy |
93,003
+500
| +0.5% | +$12.4K | ﹤0.01% | 777 |
|
|
2019
Q4 | $1.81M | Buy |
+92,503
| New | +$1.81M | ﹤0.01% | 890 |
|